A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of ACE393 to Determine Efficacy Against the Symptoms of Moderate to Severe Campylobacter Jejuni Infection in Normal Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of ACE393 to Determine Efficacy Against the Symptoms of Moderate to Severe Campylobacter Jejuni Infection in Normal Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs ACE 393 (Primary)
  • Indications Campylobacter infections; Traveller's diarrhoea
  • Focus Therapeutic Use
  • Sponsors ACE BioSciences
  • Most Recent Events

    • 11 Mar 2009 Planned number of patients changed from 60 to 72; trial IDs, centres, investigators, sponsors, start and end dates reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 10 Mar 2009 New source identified and integrated (ClinicalTrials.gov).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top